29.07.2016 21:25:00
|
Jazz Financing I Ltd. -- Moody's: Xyrem Patent Loss Is Credit Negative, but Other Patents Still Exist; Ratings Unaffected
New York, July 29, 2016 -- New York, July 28, 2016 -- Moody's Investors Service ("Moody's") commented that Jazz Securities Limited's ("Jazz")'s invalided patents is credit negative. However, there are other patents protecting Xyrem. There is no effect on Jazz's current Ba3 Corporate Family Rating. The rating outlook is negative.